ANTX
AN2 Therapeutics, Inc.NASDAQHealthcare$3.27+3.06%ClosedMarket Cap: $89.6M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
1.92
P/S
0.00
EV/EBITDA
-1.90
DCF Value
$0.59
FCF Yield
-32.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-55.0%
ROA
-56.8%
ROIC
-71.6%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | NaN% | $-9.3M | $-8.7M | $-0.29 | — |
| FY 2025 | $0.00 | NaN% | $-38.1M | $-35.2M | $-1.16 | — |
| Q3 2025 | $0.00 | NaN% | $-10.0M | $-9.4M | $-0.31 | — |
| Q2 2025 | $0.00 | NaN% | $-7.2M | $-6.5M | $-0.21 | — |
| Q1 2025 | $0.00 | NaN% | $-11.5M | $-10.6M | $-0.35 | — |
| Q4 2024 | $0.00 | NaN% | $-8.6M | $-7.5M | $-0.25 | — |
| FY 2024 | $0.00 | NaN% | $-54.6M | $-51.3M | $-1.72 | — |
| Q3 2024 | $0.00 | NaN% | $-14.0M | $-12.7M | $-0.43 | — |
| Q2 2024 | $0.00 | NaN% | $-15.9M | $-14.4M | $-0.48 | — |
| Q1 2024 | $0.00 | NaN% | $-18.3M | $-16.6M | $-0.56 | — |
| Q4 2023 | $0.00 | NaN% | $-18.8M | $-16.9M | $-0.57 | — |
| FY 2023 | $0.00 | NaN% | $-69.6M | $-64.7M | $-2.74 | — |